123 related articles for article (PubMed ID: 21212469)
1. Accuracy and optimal timing of activity measurements in estimating the absorbed dose of radioiodine in the treatment of Graves' disease.
Merrill S; Horowitz J; Traino AC; Chipkin SR; Hollot CV; Chait Y
Phys Med Biol; 2011 Feb; 56(3):557-71. PubMed ID: 21212469
[TBL] [Abstract][Full Text] [Related]
2. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
[TBL] [Abstract][Full Text] [Related]
3. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
4. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
Howarth D; Epstein M; Lan L; Tan P; Booker J
Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
[TBL] [Abstract][Full Text] [Related]
5. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
[TBL] [Abstract][Full Text] [Related]
6. Possibility of limiting the un-justified irradiation in (131)I therapy of Graves' disease: a thyroid mass-reduction based method for the optimum activity calculation.
Traino AC; Grosso M; Mariani G
Phys Med; 2010 Apr; 26(2):71-9. PubMed ID: 19800827
[TBL] [Abstract][Full Text] [Related]
7. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H
Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353
[TBL] [Abstract][Full Text] [Related]
8. Dosimetry prior to I-131-therapy of benign thyroid disease.
Hänscheid H; Lassmann M; Reiners C
Z Med Phys; 2011 Dec; 21(4):250-7. PubMed ID: 21531122
[TBL] [Abstract][Full Text] [Related]
9. Does an individual estimation of halflife improve the results of radioiodine therapy of Graves' disease?
Schneider P; Körber C; Körber-Hafner N; Hänscheid H; Reiners C
Nuklearmedizin; 2002 Dec; 41(6):240-4. PubMed ID: 12520660
[TBL] [Abstract][Full Text] [Related]
10. A dosimetric approach to patient-specific radioiodine treatment of Graves' disease with incorporation of treatment-induced changes in thyroid mass.
Traino AC; Di Martino F; Lazzeri M
Med Phys; 2004 Jul; 31(7):2121-7. PubMed ID: 15305466
[TBL] [Abstract][Full Text] [Related]
11. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
Eschner W; Kobe C; Schicha H
Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
[TBL] [Abstract][Full Text] [Related]
12. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
Urbannek V; Voth E; Moka D; Schicha H
Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200
[TBL] [Abstract][Full Text] [Related]
13. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
[TBL] [Abstract][Full Text] [Related]
14. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
[TBL] [Abstract][Full Text] [Related]
15. [Dosimetry and dose schedule of radioiodine therapy with 131 iodine].
Fueger GF
Acta Med Austriaca; 1987; 14(3-4):87-98. PubMed ID: 3321847
[TBL] [Abstract][Full Text] [Related]
16. Graves' disease radioiodine-therapy: choosing target absorbed doses for therapy planning.
Willegaignon J; Sapienza MT; Coura-Filho GB; Watanabe T; Traino AC; Buchpiguel CA
Med Phys; 2014 Jan; 41(1):012503. PubMed ID: 24387527
[TBL] [Abstract][Full Text] [Related]
17. [Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance].
Krohn T; Meyer PT; Ocklenburg C; Knollmann D; Nowak B; Schaefer WM
Nuklearmedizin; 2008; 47(6):248-54. PubMed ID: 19057798
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
19. [Radioiodine therapy of autonomously functioning thyroid nodules and Graves' disease].
Guhlmann CA; Rendl J; Börner W
Nuklearmedizin; 1995 Feb; 34(1):20-3. PubMed ID: 7724360
[TBL] [Abstract][Full Text] [Related]
20. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
